Sort
15,273 grants matching “antimicrobial resistance”
Role of Staphylococcus aureus alpha-hemolysin in disease
$390,000Juliane Bubeck Wardenburg · University Of Chicago · R01 · FY2014 · AI
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
$389,998Joseph Michael Boll · University Of Texas Dallas · R35 · FY2023 · GM
Antioxidant-based mechanisms used by staphyloccocus aureus to evade host defenses
$389,948George Y Liu · Cedars-Sinai Medical Center · R01 · FY2008 · AI
Antioxidant-based mechanisms used by staphyloccocus aureus to evade host defenses
$389,948George Y Liu · Cedars-Sinai Medical Center · R01 · FY2009 · AI
Pseudomonas aeruginosa Adaptation During Early CF Airway Infection and Treatment
$389,920Lucas R. Hoffman · University Of Washington · R01 · FY2011 · HL
Cytoskeletal Keratins in Epithelial Immunity to Bacterial Keratitis
$389,791K. P. Connie Tam · University Of California Berkeley · R01 · FY2013 · EY
Smart Self-Sterilizing Dental Composites for Class V Restorations
$389,781Carmem S. Pfeifer · Oregon Health & Science University · R01 · FY2017 · DE
The role of the tuft cell inflammasome in infection
$389,753Isabella Rauch · Oregon Health & Science University · R01 · FY2023 · AI
Modulation of Macrophage Antifungal Activity by the Transcriptional Co-regulator CITED1
$389,747David Edward Nelson · Middle Tennessee State University · R15 · FY2023 · AI
Mechanism and function of heme-iron utilization in staphylococcal pathogenesis
$389,664Eric P Skaar · Vanderbilt University · R01 · FY2012 · AI
The Impact of Calprotectin-Mediated Metal Chelation on Host-Pathogen Interactions
$389,664Eric P Skaar · Vanderbilt University · R56 · FY2011 · AI
Mechanism and function of heme-iron utilization in staphylococcal pathogenesis
$389,664Eric P Skaar · Vanderbilt University · R01 · FY2014 · AI
Mechanism and function of heme-iron utilization in staphylococcal pathogenesis
$389,664Eric P Skaar · Vanderbilt University · R01 · FY2015 · AI
The effectiveness of copper surfaces in reducing healthcare acquired infections
$389,657Daniel Zachary Uslan · University Of California Los Angeles · R01 · FY2014 · HS
The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteria
$389,523Despoina Mavridou · University Of Texas At Austin · R01 · FY2025 · AI
The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteria
$389,523Despoina Mavridou · University Of Texas At Austin · R01 · FY2024 · AI
The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteria
$389,523Despoina Mavridou · University Of Texas At Austin · R01 · FY2023 · AI
The interplay between cell envelope protein homeostasis and antibiotic resistance in Gram-negative bacteria
$389,523Despoina Mavridou · University Of Texas At Austin · R01 · FY2022 · AI
Project 3: Molecular Risk Stratification of Gastric Precancerous Lesions
$389,450Joo H Hwang · Stanford University · P01 · FY2023 · CA
THIS PROJECT WORKS ON AVIAN COLIBACILLOSIS, A MAJOR AND COSTLY INFECTIOUS DISEASE WITH MAJOR DETRIMENTAL IMPACT ON ALL FACETS OF THE POULTRY INDUSTRY WORLDWIDE. COLIBACILLOSIS IS CONSIDERED TO BE THE MOST IMPORTANT INFECTIOUS DISEASE OF POULTRY CAUSING SEVERE ECONOMIC LOSSES FROM MORTALITY, MORBIDITY, LOSS OF PRODUCTION AND CONDEMNATIONS AT PROCESSING THUS PUTTING AT RISK ONE OF THE WORLD'S CHEAPEST SOURCES OF HIGH QUALITY PROTEIN. AVIAN COLIBACILLOSIS IS CAUSED BY AVIAN PATHOGENIC ESCHERICHIA COLI (APEC). GIVEN THE WIDESPREAD INEFFECTIVENESS OF MANAGEMENT APPROACHES IN CONTROLLING APEC AS WELL AS APEC'S GROWING ANTIMICROBIAL RESISTANCE, VACCINE-BASED CONTROL APPROACHES HAVE BEEN EXTENSIVELY PURSUED IN RECENT YEARS. HOWEVER, DUE TO THE SIGNIFICANT STRAIN VARIATIONS IN APEC, PREVIOUS VACCINE-BASED APPROACHES HAVE PROVIDED ONLY LIMITED BENEFIT AS VACCINES TEND TO BE EFFECTIVE ONLY AGAINST CERTAIN SPECIFIC APEC SEROTYPES. THUS, DEVELOPMENT OF VACCINES AGAINST A WIDE RANGE OF APECIS HIGHLY DESIRABLE. ONE SUCH VACCINE TARGET IS ENTEROBACTIN (ENT), A FUNCTIONALLY CONSERVED FERRIC IRON-BINDING MOLECULE (ALSO NAMED AS 'SIDEROPHORE') IN ALL APEC; THE ENT IS A COMMON AND SIGNIFICANT MEANS USED BY DIVERSE E. COLI FOR OBTAINING IRON, A NECESSARY NUTRIENT, DURING INFECTION. RECENT STUDIES HAVE SHOWN THAT ENT-BINDING PROTEINS (INCLUDING ANTIBODIES) CAN CONTROL INFECTION BY STARVING PATHOGENS OF IRON. RECENTLY, WE HAVE SUCCESSFULLY PRODUCED ENT CONJUGATE VACCINES THAT ELICIT ENT-SPECIFIC ANTIBODIES, LEADING US TO HYPOTHESIZE THAT THE ENT CONJUGATE VACCINE CAN PREVENT AVIAN COLIBACILLOSIS CAUSED BY VARIOUS APEC. HERE, WE WILL EVALUATE THE EFFICACY OF ENT CONJUGATE VACCINE TO PROVIDE CROSS PROTECTION TO HETEROLOGOUS APEC USING DISTINCT APPROACHES. COMPLETION OF THIS PROJECT WOULD PROVIDE CRITICAL INFORMATION FOR THE DEVELOPMENT OF NOVEL, BROAD-SPECTRUM, LOW-COST, PRACTICAL AND EFFICACIOUS VACCINES AGAINST AVIAN COLIBACILLOSIS.SPECIFICALLY, WE WILL PURSUE THE FOLLOWING THREE OBJECTIVES:EVALUATE THE IMMUNOGENICITY OF THE ENT CONJUGATE VACCINE AND ITS EFFICACY IN PROTECTING BROILERS FROM COLIBACILLOSIS.ASSESS THE ENT CONJUGATE VACCINE'S ABILITY TO PREVENT COLIBACILLOSIS IN LAYERS AND YOLK SAC INFECTIONS IN THEIR HATCHLINGS.DETERMINE THE EFFICACY OF PASSIVE IMMUNIZATION USING ENT-SPECIFIC EGG YOLK ANTIBODIES FOR PROTECTING CHICKENS FROM COLIBACILLOSIS.
$389,330University Of Tennessee · · FY2018 · National Institute of Food and Agriculture
Quinolone Resistance Mechanisms in Staphylococcus aureus
$389,250Massachusetts General Hospital · R01 · FY2005 · AI
Quinolone Resistance Mechanisms in Staphylococcus aureus
$389,250Massachusetts General Hospital · R01 · FY2004 · AI
Mechanism and function of heme-iron utilization in staphylococcal pathogenesis
$389,249Eric P Skaar · Vanderbilt University · R01 · FY2011 · AI
Biofilms and Enterococcus faecalis Biology
$389,212Gary M Dunny · University Of Minnesota · R56 · FY2010 · AI
Role of MiT Transcription Factors in Host Defense Against Bacterial Infection
$389,152Javier Elbio Irazoqui · Massachusetts General Hospital · R01 · FY2014 · GM